2. Search Result
Search Result
Results for "

Antiplatelet agents

" in MedChemExpress (MCE) Product Catalog:

48

Inhibitors & Agonists

4

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10119
    Vorapaxar
    10+ Cited Publications

    SCH 530348

    		 Protease Activated Receptor (PAR) Cardiovascular Disease
    Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar
  • HY-17459
    Clopidogrel hydrogen sulfate
    Maximum Cited Publications
    30 Publications Verification

    (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate

    		 Cytochrome P450 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel hydrogen sulfate
  • HY-B0312
    Dipyridamole
    10+ Cited Publications

    		 Phosphodiesterase (PDE) Apoptosis Cardiovascular Disease Cancer
    Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .
    Dipyridamole
  • HY-118284
    Vicagrel
    1 Publications Verification

    		 P2Y Receptor Cardiovascular Disease
    Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
    Vicagrel
  • HY-10119A
    Vorapaxar sulfate
    10+ Cited Publications

    SCH 530348 sulfate

    		 Protease Activated Receptor (PAR) Cardiovascular Disease
    Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar sulfate
  • HY-B1016
    Trapidil

    AR-12008

    		 PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor Cardiovascular Disease Neurological Disease
    Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury .
    Trapidil
  • HY-A0221
    Ridogrel

    R 68070

    		 Prostaglandin Receptor Inflammation/Immunology
    Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .
    Ridogrel
  • HY-18200
    Atopaxar

    E5555; ER-172594-00

    		 Protease Activated Receptor (PAR) JAK Apoptosis Cardiovascular Disease Cancer
    Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease .
    Atopaxar
  • HY-78263
    MNS
    3 Publications Verification

    NSC 170724; 5-(2-Nitrovinyl)benzodioxole

    		 Src Syk NOD-like Receptor (NLR) Integrin PANoptosis Neurological Disease Inflammation/Immunology Cancer
    MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor, a broad-spectrum antiplatelet agent, and a PANoptosis inhibitor. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells .
    MNS
  • HY-123669A
    trans-R-138727

    		P2Y Receptor Cardiovascular Disease
    Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptor P2Y12, and inhibits ADP-induced platelet activation and aggregation .
    trans-R-138727
  • HY-118025
    (±)-2-Oxo clopidogrel

    (±)-SR-121683

    		 Drug Metabolite Others
    (±)-2-Oxo clopidogrel is a metabolite of the antiplatelet agent Clopidogrel (HY-15283) .
    (±)-2-Oxo clopidogrel
  • HY-162558
    NCGC00351170

    		Factor Xa Cardiovascular Disease
    NCGC00351170 is an antiplatelet agent that disrupts the calcium and integrin-binding protein 1 (CIB1)-αIIbβ3 interaction. NCGC00351170 inhibits thrombin-induced human platelet aggregation .
    NCGC00351170
  • HY-112575
    Tiazotic acid

    		NO Synthase Infection Cardiovascular Disease Inflammation/Immunology
    Tiazotic acid is a metabolic agent that has immunomodulatory, anti-inflammatory, antioxidant, anti-ischemic, cardio- and endothelioprotective, antiplatelet, hepatoprotective activities. Tiazotic acid increases the levels of eNOS. Tiazotic acid also reduces the level of D-dimer in the blood, which reduces the risks of heart attacks and strokes in post-COVID syndrome .
    Tiazotic acid
  • HY-N3729
    (-)-Denudatin B

    Denudatin B

    		 Calcium Channel Cardiovascular Disease
    (-)-Denudatin B is an antiplatelet agent. (-)-Denudatin B relaxed vascular smooth muscle by inhibiting the Ca2+ influx through voltage-gated and receptor-operated Ca2+ channels . And (-)-Denudatin B has nonspecific antiplatelet action
    (-)-Denudatin B
  • HY-131896
    FR144420

    NOR4

    		 NO Synthase Cardiovascular Disease
    FR144420 (NOR4) is an orally active nitric oxide (NO)-releasing agent with vasodilatory and antiplatelet effects. FR144420 induces cGMP-mediated vasodilation and inhibits platelet aggregation. FR144420 is promising for research of cardiovascular diseases, particularly angina pectoris and coronary artery spasm .
    FR144420
  • HY-18200B
    Atopaxar hydrobromide

    E5555 hydrobromide; ER 172594-06

    		 Protease Activated Receptor (PAR) JAK Apoptosis Cardiovascular Disease Cancer
    Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease .
    Atopaxar hydrobromide
  • HY-138019
    SP-8008

    		Integrin Cardiovascular Disease
    SP-8008 is a selective shear stress-induced platelet aggregation (SIPA) inhibitor with an IC50 of 1.44 μM. SP-8008 effectively interferes von Willebrand factor (vWF) and platelet glycoprotein (GP) Ib interaction. SP-8008 exerts its antithrombotic effect by selectively inhibiting shear stress-induced platelet aggregation .
    SP-8008
  • HY-B1016R
    Trapidil (Standard)

    AR-12008 (Standard)

    		 Reference Standards PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor Cardiovascular Disease Cancer
    Trapidil (Standard) (AR-12008 (Standard)) is the analytical standard of Trapidil (HY-B1016R). This product is intended for research and analytical applications. Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury.
    Trapidil (Standard)
  • HY-N1861
    3-O-Methylquercetin tetraacetate

    Quercetin 3-O-methyl ether peracetate

    		 P2Y Receptor Cardiovascular Disease Cancer
    3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .
    3-O-Methylquercetin tetraacetate
  • HY-146499
    Antiplatelet agent 2

    		P2Y Receptor Cardiovascular Disease Cancer
    Antiplatelet agent 2 (compound 7p) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 2 can be used for researching platelet aggregation .
    Antiplatelet agent 2
  • HY-146498
    Antiplatelet agent 1

    		P2Y Receptor Cardiovascular Disease Cancer
    Antiplatelet agent 1 (compound 7q) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 1 can be used for researching platelet aggregation .
    Antiplatelet agent 1
  • HY-173207
    Antiplatelet agent 3

    		Thrombin Cardiovascular Disease
    Antiplatelet agent 3 (Compound K-10) is a compound with anti-platelet aggregation activity. The IC50 values for platelet aggregation induced by ADP, AA and COL are 2.55, 3.22 and 2.09 mg/mL, respectively. Antiplatelet agent 3 is expected to be used in the research of cardiovascular diseases .
    Antiplatelet agent 3
  • HY-N1723
    2-Deacetoxytaxinine B

    		Others Cardiovascular Disease
    2-Deacetoxytaxinine B is a potent antiplatelet agent .
    2-Deacetoxytaxinine B
  • HY-N3048
    Piperlotine D

    		Others Cardiovascular Disease
    Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC50 of 43.4 μg/mL .
    Piperlotine D
  • HY-U00039
    Desethyl KBT-3022

    		Thrombin Cardiovascular Disease
    Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022.
    Desethyl KBT-3022
  • HY-119410
    Linotroban

    HN11500

    		 Prostaglandin Receptor Cardiovascular Disease
    Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent .
    Linotroban
  • HY-118025R
    (±)-2-Oxo clopidogrel (Standard)

    (±)-SR-121683 (Standard)

    		 Drug Metabolite Reference Standards Others
    (±)-2-Oxo clopidogrel (Standard) is the analytical standard of (±)-2-Oxo clopidogrel. This product is intended for research and analytical applications. (±)-2-Oxo clopidogrel is a metabolite of the antiplatelet agent Clopidogrel (HY-15283) .
    (±)-2-Oxo clopidogrel (Standard)
  • HY-106080A
    Furegrelate sodium

    U-63557A

    		 Prostaglandin Receptor Cardiovascular Disease
    Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
    Furegrelate sodium
  • HY-106080
    Furegrelate

    U-63557A free acid

    		 Prostaglandin Receptor Cardiovascular Disease
    Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent .
    Furegrelate
  • HY-141749AS
    Clopidogrel carboxylic acid-d4

    CLPM-d4; SR 26334-d4

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Clopidogrel carboxylic acid-d4 is a deuterated derivative of Clopidogrel carboxylic acid, which is an inactive metabolite of the antiplatelet agent Clopidogrel (HY-15283) in plasma. Clopidogrel carboxylic acid-d4 can be used to further explore the metabolic characteristics of Clopidogrel .
    Clopidogrel carboxylic acid-d4
  • HY-125615
    DMP 728 methanesulfonate

    		Glycoprotein VI Cardiovascular Disease Others
    DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .
    DMP 728 methanesulfonate
  • HY-B0312R
    Dipyridamole (Standard)

    		Reference Standards Phosphodiesterase (PDE) Apoptosis Cardiovascular Disease Cancer
    Dipyridamole (Standard) is the analytical standard of Dipyridamole. This product is intended for research and analytical applications. Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .
    Dipyridamole (Standard)
  • HY-106080AR
    Furegrelate sodium (Standard)

    U-63557A (Standard)

    		 Prostaglandin Receptor Reference Standards Cardiovascular Disease
    Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
    Furegrelate sodium (Standard)
  • HY-10119R
    Vorapaxar (Standard)

    SCH 530348 (Standard)

    		 Reference Standards Protease Activated Receptor (PAR) Cardiovascular Disease
    Vorapaxar (Standard) is the analytical standard of Vorapaxar. This product is intended for research and analytical applications. Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar (Standard)
  • HY-10119S
    Vorapaxar-d5

    SCH 530348-d5

    		 Protease Activated Receptor (PAR) Isotope-Labeled Compounds Cardiovascular Disease
    Vorapaxar-d5 is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar-d5
  • HY-115911
    GPVI antagonist 2

    		Glycoprotein VI Cardiovascular Disease
    GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .
    GPVI antagonist 2
  • HY-10119AR
    Vorapaxar sulfate (Standard)

    SCH 530348 sulfate (Standard)

    		 Reference Standards Protease Activated Receptor (PAR) Cardiovascular Disease
    Vorapaxar (sulfate) (Standard) is the analytical standard of Vorapaxar (sulfate). This product is intended for research and analytical applications. Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
    Vorapaxar sulfate (Standard)
  • HY-115912
    GPVI antagonist 3

    		Glycoprotein VI Cardiovascular Disease
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .
    GPVI antagonist 3
  • HY-17459R
    Clopidogrel hydrogen sulfate (Standard)

    (S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)

    		 Reference Standards Cytochrome P450 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel hydrogen sulfate (Standard)
  • HY-17459S
    Clopidogrel-d3 hydrogen sulfate

    (S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate

    		 P2Y Receptor Cytochrome P450 Cardiovascular Disease
    Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate . Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel-d3 hydrogen sulfate
  • HY-160615
    TP receptor antagonist-1

    		Prostaglandin Receptor Cardiovascular Disease Inflammation/Immunology
    TP receptor antagonist-1 (compound 7m) is a thromboxane A2 receptor (TP receptor) antagonist, with IC50 values of 9.46 μM for TPa and 8.49 μM for TPb, respectively. TP receptor antagonist-1 can be used for the research of cardiovascular disease .
    TP receptor antagonist-1
  • HY-171241
    Imolamine

    		Drug Derivative Cardiovascular Disease
    Imolamine is a potent antiplatelet aggregation agent, is a phenyl aminoxidiazole derivative. Imolamine has the potential for the research of coronary heart disease .
    Imolamine
  • HY-106046
    Itazigrel

    U-53059

    		 COX Cardiovascular Disease
    Itazigrel (U-53059) is an orally active antiplatelet agent. Itazigrel inhibits cyclooxygenase activity. Itazigrel inhibits platelet aggregation .
    Itazigrel
  • HY-W744340
    2-Oxo Clopidogrel-d3

    		Isotope-Labeled Compounds Others
    2-Oxo Clopidogrel-d3 is the deuterium labeled (±)-2-Oxo clopidogrel (HY-118025). (±)-2-Oxo clopidogrel is a metabolite of the antiplatelet agent Clopidogrel (HY-15283) .
    2-Oxo Clopidogrel-d3
  • HY-167743
    Platelet aggregation-IN-2

    		Endogenous Metabolite Cardiovascular Disease
    Platelet aggregation-IN-2 is an anti-platelet aggregation agent with significant anticoagulant activity. Platelet aggregation-IN-2 can inhibit platelet aggregation reaction and reduce the risk of thrombosis. The application of Platelet aggregation-IN-2 can potentially be used for the prevention and suppression of cardiovascular diseases .
    Platelet aggregation-IN-2
  • HY-179302
    SD3A

    		Mitochondrial Metabolism Integrin Cardiovascular Disease
    SD3A is an antiplatelet agent. SD3A inhibits granule secretion and GP IIb/IIIa activation. SD3A inhibits mitochondrial function. SD3A has an antiaggregant effect on washed platelets stimulated with Collagen. SD3A results in reduced thrombus formation without affecting coagulation .
    SD3A
  • HY-W169940
    NP-184

    		Prostaglandin Receptor Cardiovascular Disease
    NP-184 is a novel orally active antithrombotic agent. NP-184 selectively inhibits TXA2 synthase activity with an IC50 value of 4.3 μM. NP-184 has antiplatelet and antithrombotic activities. NP-184 can be used in the research of thromboembolic diseases .
    NP-184
  • HY-A0221R
    Ridogrel (Standard)

    R 68070 (Standard)

    		 Prostaglandin Receptor Reference Standards Inflammation/Immunology
    Ridogrel (Standard) is the analytical standard of Ridogrel. This product is intended for research and analytical applications. Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .
    Ridogrel (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: